Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 14, 2008
Event: Entry into a Material Definitive Agreement regarding a private placement of securities.
Key Financial Metrics
This filing reports on a capital raise event rather than periodic operating results. Specific metrics include:
- Gross Proceeds: Approximately $5,000,000.
- Common Stock Issued: 8,524,669 shares at $0.60 per share.
- Warrants Issued: Three-year warrants to purchase 4,262,337 shares at an exercise price of $0.90 per share.
- Transaction Costs: $85,000 cash finder's fee and 143,333 shares issued as finder's fees to four individuals.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operating metrics.
Material Changes
The primary material change is the increase in equity capital and the dilution of existing shareholders due to the issuance of new shares and warrants. The company raised approximately $5 million from twenty-nine accredited investors.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the completion of the private placement but does not contain specific forward-looking guidance or operational outlook within the text provided.
Risks and Contingencies: The securities were issued under Section 4(2) of the Securities Act of 1933 as a transaction not involving a public offering, limited to accredited investors. No specific operational risks or contingencies are detailed in this excerpt.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the use of proceeds for the $5 million raised (not specified in this text).
- Review the attached Press Release (Exhibit 99.1) for management's strategic intent.
- Examine the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants.
- Check subsequent filings for the impact of the $85,000 cash fee and share-based compensation on cash reserves.